María Adela Aguirre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Adela Aguirre has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Elsa Nucifora
Servicio de Hematología, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
12 shared publications - María Lourdes Posadas-Martínez
Hospital Italiano de Buenos Aires
11 shared publications - Diego Pérez de Arenaza
Servicio de Cardiología, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
7 shared publications - Marcelina Carretero
Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
6 shared publications - Santiago Decotto
Servicio de Cardiología, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
6 shared publications Patricia Sorroche
Affiliation Internal Medicine Department, Biochemestry Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
5 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7725-7738
Diagnostic accuracy of fat pad sampling and bone marrow biopsy for AL amyloidosis: a systematic review and meta-analysis
In this systematic review, we aimed to assess the diagnostic test accuracy of abdominal fat pad sampling and bone marrow biopsy for immunoglobulin light-chain amyloidosis using organ biopsy as the reference standard. We searched the literature using PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to March 2024. We used Quality Assessment of Diagnostic Accuracy Studies-2 to assess the risk of bias and the Grading of Recommendations Assessment, Development, and Evaluation approach to assess the certainty of evidence. After deduplication, 29 237 records were screened and 31 studies were included. Among the studies, 25 (n = 4649) reported on fat pad sampling, with a pooled sensitivity of 0.77 (95% confidence interval, 0.72-0.81), whereas 20 (n = 2771) reported on bone marrow biopsy, with a pooled sensitivity of 0.55 (0.46-0.63). All studies enrolled patients with confirmed disease; specificity was not reported in the included studies. Fat pad aspiration (15 studies, n = 1590) and surgical or punch biopsy (4 studies, n = 222) had similar sensitivities of 0.80 (0.76-0.83) and 0.77 (0.61-0.88), respectively. In a single study (n = 612), performing both tests together yielded a sensitivity of 0.89. Certainty of evidence was judged to be moderate for fat pad sampling and low for bone marrow biopsy.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7725-7738
Diagnostic accuracy of fat pad sampling and bone marrow biopsy for AL amyloidosis: a systematic review and meta-analysis
In this systematic review, we aimed to assess the diagnostic test accuracy of abdominal fat pad sampling and bone marrow biopsy for immunoglobulin light-chain amyloidosis using organ biopsy as the reference standard. We searched the literature using PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to March 2024. We used Quality Assessment of Diagnostic Accuracy Studies-2 to assess the risk of bias and the Grading of Recommendations Assessment, Development, and Evaluation approach to assess the certainty of evidence. After deduplication, 29 237 records were screened and 31 studies were included. Among the studies, 25 (n = 4649) reported on fat pad sampling, with a pooled sensitivity of 0.77 (95% confidence interval, 0.72-0.81), whereas 20 (n = 2771) reported on bone marrow biopsy, with a pooled sensitivity of 0.55 (0.46-0.63). All studies enrolled patients with confirmed disease; specificity was not reported in the included studies. Fat pad aspiration (15 studies, n = 1590) and surgical or punch biopsy (4 studies, n = 222) had similar sensitivities of 0.80 (0.76-0.83) and 0.77 (0.61-0.88), respectively. In a single study (n = 612), performing both tests together yielded a sensitivity of 0.89. Certainty of evidence was judged to be moderate for fat pad sampling and low for bone marrow biopsy.
- 1 November 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 52 (2)
Prognostic value of right ventricular ejection fraction measured by cardiac magnetic resonance in patients with transthyretin amyloidosis
- 1 November 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 52 (2)
Prognostic value of right ventricular ejection fraction measured by cardiac magnetic resonance in patients with transthyretin amyloidosis
- Open Access
- 8 October 2026
- Published by SAABRON PRESS in Clinical Hematology International: Case Reports
- Vol. 1 (4)
Acute promyelocytic leukemia in pregnancy: Balancing treatment and toxicity
Acute promyelocytic leukemia (APL) during pregnancy is an exceptionally rare event, estimated at fewer than 1 per 100,000 pregnancies, reflecting the convergence of a hematologic emergency and the therapeutic challenges of gestation [1]. We report a 37-year-old woman at 22 weeks of gestation, referred for lower-limb edema and extensive bruising. Laboratory workup showed severe pancytopenia with early coagulopathy. Bone marrow examination confirmed APL by flow cytometry, cytogenetics, and molecular studies, which demonstrated the t(15;17) translocation and the PML-RARA fusion transcript [2]. Multidisciplinary assessment led to treatment with all-trans retinoic acid (ATRA); arsenic trioxide (ATO) was withheld for its teratogenic potential [2–4]. The course was complicated by differentiation syndrome, disseminated intravascular coagulation, and progressive obstetric deterioration, requiring corticosteroids, ICU admission, and dynamic adjustments [2,3,5,6]. Cesarean delivery occurred at 30 weeks of gestation with intensive transfusion support. The patient is now on ATRA/ATO consolidation with favorable evolution; the newborn, after prematurity-related complications, has been discharged from the neonatal ICU. This case, together with a focused review of the available literature, illustrates the complexity of managing APL during pregnancy and highlights continuous inpatient care, multidisciplinary collaboration, and real-time decision-making as central to its management [1-3].
- 8 October 2026
- Published by SAABRON PRESS in Clinical Hematology International: Case Reports
- Vol. 1 (4)
Open AccessAcute promyelocytic leukemia in pregnancy: Balancing treatment and toxicity
Acute promyelocytic leukemia (APL) during pregnancy is an exceptionally rare event, estimated at fewer than 1 per 100,000 pregnancies, reflecting the convergence of a hematologic emergency and the therapeutic challenges of gestation [1]. We report a 37-year-old woman at 22 weeks of gestation, referred for lower-limb edema and extensive bruising. Laboratory workup showed severe pancytopenia with early coagulopathy. Bone marrow examination confirmed APL by flow cytometry, cytogenetics, and molecular studies, which demonstrated the t(15;17) translocation and the PML-RARA fusion transcript [2]. Multidisciplinary assessment led to treatment with all-trans retinoic acid (ATRA); arsenic trioxide (ATO) was withheld for its teratogenic potential [2–4]. The course was complicated by differentiation syndrome, disseminated intravascular coagulation, and progressive obstetric deterioration, requiring corticosteroids, ICU admission, and dynamic adjustments [2,3,5,6]. Cesarean delivery occurred at 30 weeks of gestation with intensive transfusion support. The patient is now on ATRA/ATO consolidation with favorable evolution; the newborn, after prematurity-related complications, has been discharged from the neonatal ICU. This case, together with a focused review of the available literature, illustrates the complexity of managing APL during pregnancy and highlights continuous inpatient care, multidisciplinary collaboration, and real-time decision-making as central to its management [1-3].
- Open Access
- 21 May 2026
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Amiloidosis cardíaca por transtiretina: diferencias clínicas, imagenológicas y evolutivas según el sexo
Introducción: La cardiopatía amiloidótica por transtiretina (CA-TTR) es una entidad cuyo diagnóstico es cada vez más frecuente. Se han descripto diferencias en la presentación clínica y en la evolución según el sexo, sin embargo, no contamos con información local que describa estas diferencias. Objetivo: Describir las diferencias en la presentación clínica, las características imagenológicas al diagnóstico y la evolución de pacientes con diagnóstico de CA-TTR según el sexo. Materiales y métodos: Estudio de cohorte retrospectivo, multicéntrico (dos centros), que incluyó pacientes con diagnóstico de CA-TTR entre 2010 y 2025. Las variables clínicas, electrocardiográficas e imagenológicas al momento del diagnóstico, así como los eventos durante el seguimiento, se obtuvieron a partir de la historia clínica electrónica institucional. Se compararon las características basales entre hombres y mujeres mediante pruebas estadísticas apropiadas. Se realizaron curvas de Kaplan-Meier para estimar la incidencia de mortalidad por cualquier causa, internaciones por insuficiencia cardíaca y un punto final combinado de ambos eventos. Resultados: Se incluyeron 186 pacientes, 153 hombres (82,2%) y 33 mujeres (17,8%). Las mujeres fueron diagnosticadas a mayor edad (83 vs. 80 años; p = 0,042). En el ecocardiograma basal, presentaron menor espesor septal y de la pared posterior (14,8 vs. 16,9 mm; p = 0,020 y 12,7 vs. 14,3 mm; p = 0,005, respectivamente) en comparación con los hombres. En la resonancia magnética cardíaca (n = 108), las mujeres mostraron mayor fracción de eyección del ventrículo izquierdo y derecho (62% vs. 50%; p = 0,031 y 56% vs. 47%; p = 0,011, respectivamente) y menor espesor parietal máximo (16,4 mm vs. 18,7 mm; p = 0,013). Durante una mediana de seguimiento de 725,5 días (rango intercuartílico, RIC, 342,5–1220), no se observaron diferencias estadísticamente significativas en la mortalidad ni en internaciones por insuficiencia cardíaca entre ambos sexos. Conclusiones: En esta cohorte nacional de pacientes con CA-TTR, las mujeres fueron diagnosticadas a mayor edad y presentaron menor compromiso miocárdico estructural y funcional al momento del diagnóstico. Sin embargo, estas diferencias no se tradujeron en un impacto significativo en la evolución clínica durante el seguimiento.
- 21 May 2026
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessAmiloidosis cardíaca por transtiretina: diferencias clínicas, imagenológicas y evolutivas según el sexo
Introducción: La cardiopatía amiloidótica por transtiretina (CA-TTR) es una entidad cuyo diagnóstico es cada vez más frecuente. Se han descripto diferencias en la presentación clínica y en la evolución según el sexo, sin embargo, no contamos con información local que describa estas diferencias. Objetivo: Describir las diferencias en la presentación clínica, las características imagenológicas al diagnóstico y la evolución de pacientes con diagnóstico de CA-TTR según el sexo. Materiales y métodos: Estudio de cohorte retrospectivo, multicéntrico (dos centros), que incluyó pacientes con diagnóstico de CA-TTR entre 2010 y 2025. Las variables clínicas, electrocardiográficas e imagenológicas al momento del diagnóstico, así como los eventos durante el seguimiento, se obtuvieron a partir de la historia clínica electrónica institucional. Se compararon las características basales entre hombres y mujeres mediante pruebas estadísticas apropiadas. Se realizaron curvas de Kaplan-Meier para estimar la incidencia de mortalidad por cualquier causa, internaciones por insuficiencia cardíaca y un punto final combinado de ambos eventos. Resultados: Se incluyeron 186 pacientes, 153 hombres (82,2%) y 33 mujeres (17,8%). Las mujeres fueron diagnosticadas a mayor edad (83 vs. 80 años; p = 0,042). En el ecocardiograma basal, presentaron menor espesor septal y de la pared posterior (14,8 vs. 16,9 mm; p = 0,020 y 12,7 vs. 14,3 mm; p = 0,005, respectivamente) en comparación con los hombres. En la resonancia magnética cardíaca (n = 108), las mujeres mostraron mayor fracción de eyección del ventrículo izquierdo y derecho (62% vs. 50%; p = 0,031 y 56% vs. 47%; p = 0,011, respectivamente) y menor espesor parietal máximo (16,4 mm vs. 18,7 mm; p = 0,013). Durante una mediana de seguimiento de 725,5 días (rango intercuartílico, RIC, 342,5–1220), no se observaron diferencias estadísticamente significativas en la mortalidad ni en internaciones por insuficiencia cardíaca entre ambos sexos. Conclusiones: En esta cohorte nacional de pacientes con CA-TTR, las mujeres fueron diagnosticadas a mayor edad y presentaron menor compromiso miocárdico estructural y funcional al momento del diagnóstico. Sin embargo, estas diferencias no se tradujeron en un impacto significativo en la evolución clínica durante el seguimiento.
- 21 April 2026
- Published by Revista Argentina de Cardiologia
- Vol. 94 (2) , 120-126
Clinical, Imaging, and Disease Progression Sex-related Differences in Transthyretin Cardiac Amyloidosis
- 21 April 2026
- Published by Revista Argentina de Cardiologia
- Vol. 94 (2) , 120-126
Clinical, Imaging, and Disease Progression Sex-related Differences in Transthyretin Cardiac Amyloidosis
- Open Access
- 14 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5293-5307
Diagnostic Utility of Immunofixation and Free Light Chain Assay in AL Amyloidosis: A Systematic Review and Meta-analysis
In this systematic review, we aimed to assess the sensitivity of serum and urine immunofixation (IFE) and serum free light chain (sFLC) in detecting plasma cell dyscrasia (PCD) associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of IFE and/or sFLC in patients with AL amyloidosis. We used the GRADE approach to assess the certainty of evidence and QUADAS-2 to assess the risk of bias. After deduplication, 29,237 records were screened, and 44 studies (n = 18,071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3,390), 24 studies for UIFE (n = 2,830), 19 studies for SIFE and UIFE (n = 2,819), 21 studies for sFLC ratio (n = 3,678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all three tests (n = 1,430). Pooled sensitivities were: SIFE 0.68 (95% CI 0.62-0.73), UIFE 0.77 (0.72-0.81), SIFE and UIFE 0.89 (0.84-0.93), sFLC ratio 0.82 (0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
- 14 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5293-5307
Open AccessDiagnostic Utility of Immunofixation and Free Light Chain Assay in AL Amyloidosis: A Systematic Review and Meta-analysis
In this systematic review, we aimed to assess the sensitivity of serum and urine immunofixation (IFE) and serum free light chain (sFLC) in detecting plasma cell dyscrasia (PCD) associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of IFE and/or sFLC in patients with AL amyloidosis. We used the GRADE approach to assess the certainty of evidence and QUADAS-2 to assess the risk of bias. After deduplication, 29,237 records were screened, and 44 studies (n = 18,071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3,390), 24 studies for UIFE (n = 2,830), 19 studies for SIFE and UIFE (n = 2,819), 21 studies for sFLC ratio (n = 3,678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all three tests (n = 1,430). Pooled sensitivities were: SIFE 0.68 (95% CI 0.62-0.73), UIFE 0.77 (0.72-0.81), SIFE and UIFE 0.89 (0.84-0.93), sFLC ratio 0.82 (0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
- Top Cited PapersOpen Access
- 27 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5113-5152
American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis
Light chain (AL) amyloidosis is a rare disease caused by the misfolding of immunoglobulin light chains produced by a plasma cell dyscrasia. Patients can present with involvement of many organs, including the heart, kidneys, liver, nerves and other sites, resulting in a high symptom burden. Timely and accurate diagnosis is important to prevent organ failure and improve patient survival. These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients and clinicians in the timely and effective diagnosis of AL amyloidosis. ASH formed a multidisciplinary guideline panel that included 22 individuals representing various medical specialties (academic/community hematology, nephrology, neurology, cardiology, internal medicine and pathology) as well as one patient representative. The group was balanced to minimize potential bias from conflicts of interest. Kansas University Medical Center supported the guideline development process, including updating or performing systematic evidence reviews (up to 6th of March 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. The panel agreed on 12 recommendations. The use of serum immunofixation, urine immunofixation and serum free light chains enhances the clinical suspicion of AL amyloidosis. The diagnosis of AL amyloidosis can be made effectively through surrogate biopsies which require both a bone marrow biopsy and fat pad sampling However, target organ biopsies maybe favoured in certain clinical situations.
- 27 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5113-5152
Top Cited PapersOpen AccessAmerican Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis
Light chain (AL) amyloidosis is a rare disease caused by the misfolding of immunoglobulin light chains produced by a plasma cell dyscrasia. Patients can present with involvement of many organs, including the heart, kidneys, liver, nerves and other sites, resulting in a high symptom burden. Timely and accurate diagnosis is important to prevent organ failure and improve patient survival. These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients and clinicians in the timely and effective diagnosis of AL amyloidosis. ASH formed a multidisciplinary guideline panel that included 22 individuals representing various medical specialties (academic/community hematology, nephrology, neurology, cardiology, internal medicine and pathology) as well as one patient representative. The group was balanced to minimize potential bias from conflicts of interest. Kansas University Medical Center supported the guideline development process, including updating or performing systematic evidence reviews (up to 6th of March 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. The panel agreed on 12 recommendations. The use of serum immunofixation, urine immunofixation and serum free light chains enhances the clinical suspicion of AL amyloidosis. The diagnosis of AL amyloidosis can be made effectively through surrogate biopsies which require both a bone marrow biopsy and fat pad sampling However, target organ biopsies maybe favoured in certain clinical situations.
- Open Access
- 27 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5097-5112
Clinical Features of Systemic Amyloidosis: A Scoping Review
Systemic amyloidosis is a rare, multisystem disorder that is often challenging to diagnose due to vague and non-specific symptoms that frequently overlap with other disorders. By the time patients are diagnosed, irreversible organ impairment from amyloid deposition has occurred, contributing to substantial morbidity and mortality. While developing the American Society of Hematology (ASH) guidelines on systemic amyloidosis, we identified a critical knowledge gap in the recognition of the clinical presentation of its most common subtypes. Therefore, we conducted a scoping review of 117 studies following PRISMA-ScR guidelines to identify clinical "red flags" for light chain (AL) and transthyretin (ATTRwt, ATTRv) amyloidosis. Studies were identified from the comprehensive systematic review through the ASH amyloidosis diagnosis guideline panel, data mining, and grey literature review. Data were extracted and synthesized by systems to characterize the earliest and most frequently overlooked clinical red flags for the different types of amyloidosis. Shortness of breath and fatigue, the earliest symptoms of AL amyloidosis, contrast with the carpal tunnel syndrome occurring years before ATTRwt cardiac amyloidosis is diagnosed. Weight loss, unexplained abdominal pain, and early satiety were overlooked red flags for AL amyloidosis, compared to the preceding arrhythmias often missed in evaluation for ATTRwt amyloidosis. Sensory loss was the predominant neuropathic presentation for AL amyloidosis compared to the painful length-dependent neuropathy of ATTRv amyloidosis. Awareness of the early symptoms and distinct patterns across subtypes can enhance cross-specialty awareness and support earlier diagnosis and intervention of AL and ATTR amyloidosis.
- 27 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5097-5112
Open AccessClinical Features of Systemic Amyloidosis: A Scoping Review
Systemic amyloidosis is a rare, multisystem disorder that is often challenging to diagnose due to vague and non-specific symptoms that frequently overlap with other disorders. By the time patients are diagnosed, irreversible organ impairment from amyloid deposition has occurred, contributing to substantial morbidity and mortality. While developing the American Society of Hematology (ASH) guidelines on systemic amyloidosis, we identified a critical knowledge gap in the recognition of the clinical presentation of its most common subtypes. Therefore, we conducted a scoping review of 117 studies following PRISMA-ScR guidelines to identify clinical "red flags" for light chain (AL) and transthyretin (ATTRwt, ATTRv) amyloidosis. Studies were identified from the comprehensive systematic review through the ASH amyloidosis diagnosis guideline panel, data mining, and grey literature review. Data were extracted and synthesized by systems to characterize the earliest and most frequently overlooked clinical red flags for the different types of amyloidosis. Shortness of breath and fatigue, the earliest symptoms of AL amyloidosis, contrast with the carpal tunnel syndrome occurring years before ATTRwt cardiac amyloidosis is diagnosed. Weight loss, unexplained abdominal pain, and early satiety were overlooked red flags for AL amyloidosis, compared to the preceding arrhythmias often missed in evaluation for ATTRwt amyloidosis. Sensory loss was the predominant neuropathic presentation for AL amyloidosis compared to the painful length-dependent neuropathy of ATTRv amyloidosis. Awareness of the early symptoms and distinct patterns across subtypes can enhance cross-specialty awareness and support earlier diagnosis and intervention of AL and ATTR amyloidosis.
- 25 November 2025
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (2) , 103216
External validation of a predictive model for diagnosing transthyretin cardiac amyloidosis in suspected cases
- 25 November 2025
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (2) , 103216
External validation of a predictive model for diagnosing transthyretin cardiac amyloidosis in suspected cases
- Open Access
- 19 September 2025
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 6 (3) , 112-119
Valvulopatías significativas en amiloidosis por transtiretina wild-type: prevalencia e impacto en la sobrevida
Objetivo. Existen pocos datos sobre la prevalencia de valvulopatías significativas en pacientes con amiloidosis cardíaca por transtiretina wild type (ATTRwt). El objetivo de este estudio fue describir la prevalencia de estenosis aórtica (EA), insuficiencia mitral (IM) e insuficiencia tricuspídea (IT) en esta población y, de forma secundaria, evaluar su impacto en la sobrevida. Materiales y métodos. Estudio de cohorte retrospectivo, unicéntrico, que incluyó pacientes con diagnóstico de ATTRwt entre 2011 y 2024. Se calculó la prevalencia de cada valvulopatía significativa y se elaboraron curvas de Kaplan-Meier para estimar la incidencia de muerte por cualquier causa a dos años de seguimiento, estratificada por la presencia o ausencia de cada una de las valvulopatías. Finalmente, se realizó un análisis multivariado de Cox para evaluar su relación con la sobrevida. Resultados. Se incluyeron 154 pacientes; la edad media fue de 81 (±7) años y el 85% (n=131) fueron hombres. La IT significativa fue la valvulopatía más prevalente (27%, n=41), seguida por la IM (20%, n=30) y la EA (13%, n=20). Los pacientes con IT significativa presentaron una mayor incidencia de mortalidad por cualquier causa comparados con los pacientes sin IT significativa (41% vs. 16%, Log-Rank p=0,0007), y no se observaron diferencias entre los pacientes con y sin EA e IM significativas. En los modelos multivariados, la IT significativa se asoció con mayor mortalidad independientemente de la edad, de la presencia de otras valvulopatías y de los niveles de NT-proBNP. Conclusiones. La IT significativa fue la valvulopatía más prevalente en pacientes con ATTRwt y se asoció a una menor sobrevida en esta población.
- 19 September 2025
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 6 (3) , 112-119
Open AccessValvulopatías significativas en amiloidosis por transtiretina wild-type: prevalencia e impacto en la sobrevida
Objetivo. Existen pocos datos sobre la prevalencia de valvulopatías significativas en pacientes con amiloidosis cardíaca por transtiretina wild type (ATTRwt). El objetivo de este estudio fue describir la prevalencia de estenosis aórtica (EA), insuficiencia mitral (IM) e insuficiencia tricuspídea (IT) en esta población y, de forma secundaria, evaluar su impacto en la sobrevida. Materiales y métodos. Estudio de cohorte retrospectivo, unicéntrico, que incluyó pacientes con diagnóstico de ATTRwt entre 2011 y 2024. Se calculó la prevalencia de cada valvulopatía significativa y se elaboraron curvas de Kaplan-Meier para estimar la incidencia de muerte por cualquier causa a dos años de seguimiento, estratificada por la presencia o ausencia de cada una de las valvulopatías. Finalmente, se realizó un análisis multivariado de Cox para evaluar su relación con la sobrevida. Resultados. Se incluyeron 154 pacientes; la edad media fue de 81 (±7) años y el 85% (n=131) fueron hombres. La IT significativa fue la valvulopatía más prevalente (27%, n=41), seguida por la IM (20%, n=30) y la EA (13%, n=20). Los pacientes con IT significativa presentaron una mayor incidencia de mortalidad por cualquier causa comparados con los pacientes sin IT significativa (41% vs. 16%, Log-Rank p=0,0007), y no se observaron diferencias entre los pacientes con y sin EA e IM significativas. En los modelos multivariados, la IT significativa se asoció con mayor mortalidad independientemente de la edad, de la presencia de otras valvulopatías y de los niveles de NT-proBNP. Conclusiones. La IT significativa fue la valvulopatía más prevalente en pacientes con ATTRwt y se asoció a una menor sobrevida en esta población.